Tag: paclitaxel-coated devices

PCBs: Panel of vascular surgeons review latest findings on paclitaxel-coated balloons

A recent meta-analysis by Konstantinos Katsanos, MD, of Patras University Hospital, Rion, Greece, and colleagues—“Risk of major amputation following application of paclitaxel-coated balloons ...

VAM discussion on latest paclitaxel meta-analysis yields mix of caution, skepticism

A Vascular Annual Meeting (VAM) sponsored session on paclitaxel safety drew a mix of skeptical and cautious responses to the latest meta-analysis from interventional...

Latest meta-analysis on paclitaxel in peripheral arterial disease provokes mixed reception

“There appears to be heightened risk of major amputation after use of paclitaxel-coated balloons in the peripheral arteries,” findings from a systematic review...

Veterans study: No evidence of increased risk of death with use...

A study of more than 10,000 U.S. veterans with peripheral arterial disease (PAD) undergoing endovascular interventions in the femoropopliteal segment found that rates of...

LINC 2021: Long-term data show sustained efficacy and safety of paclitaxel...

A key theme among the late-breaking trial data presented at the recent LINC 2021 (the Leipzig Interventional Course), held digitally from Jan. 25–29, was the...

‘Ample published data unable to replicate association between paclitaxel-coated devices and...

Ample published data from from large, observational datasets, randomized-controlled trial (RCT) subgroup analyses and long-term follow-up from pivotal paclitaxel-coated device RCTs have not been...

CX 2020 LIVE pioneers virtual vascular conference format in COVID-19 era

CX 2020 LIVE came to life online—despite COVID-19—using state-of-the art broadcast technology to bring together more than 1,000 vascular specialists, live, from 95 countries across...

VIVA Physicians publishes analysis evaluating mortality and paclitaxel-coated devices

An individual patient-level data (IPD) analysis of the safety of paclitaxel-containing devices (PTXD), conducted by VIVA Physicians, identified an absolute 4.6% increased mortality risk...